Melanotan I Dosage Guide
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Dosage overview
| Typical dose | 16 mg subcutaneous implant (FDA-approved for EPP) |
| Frequency | Every 2 months (implant) |
| Cycle length | Ongoing as prescribed |
Dosing notes
Scenesse is administered as a subcutaneous implant by a healthcare provider, not self-injected. The implant slowly releases afamelanotide over approximately 60 days. Available through specialty pharmacies only. Research peptide versions are also available as lyophilized powder for subcutaneous injection, but these are not FDA-approved formulations.
FDA-approved indications
Melanotan I is FDA-approved for: Erythropoietic protoporphyria (EPP) in adults (Scenesse).
Off-label use should only be pursued under the guidance of a licensed healthcare provider.
Important safety information
Dosage ranges listed above are based on published clinical trial protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.
- Start at the lowest effective dose and titrate up gradually
- Monitor for side effects, especially during dose increases
- Do not exceed researched dose ranges without medical supervision
Research references
- Afamelanotide for Erythropoietic Protoporphyria — New England Journal of Medicine (2015) [PubMed]
- Three-year observational study of afamelanotide in erythropoietic protoporphyria — British Journal of Dermatology (2020) [PubMed]
- Tanning and cutaneous melanin synthesis with subcutaneous melanotan-I and UV exposure — Journal of Investigative Dermatology (2004) [PubMed]
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.